Alkermes plc - Ordinary Shares (ALKS): Price and Financial Metrics

Alkermes plc - Ordinary Shares (ALKS)

Today's Latest Price: $22.85 USD

0.48 (2.15%)

Updated Jan 19 4:00pm

Add ALKS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ALKS Stock Summary

  • ALKS's went public 29.53 years ago, making it older than 83.32% of listed US stocks we're tracking.
  • The price/operating cash flow metric for Alkermes plc is higher than 92.36% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of 31.62%, Alkermes plc's debt growth rate surpasses 76.43% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Alkermes plc, a group of peers worth examining would be EMKR, PSNL, RIGL, BBI, and ATNX.
  • ALKS's SEC filings can be seen here. And to visit Alkermes plc's official web site, go to

ALKS Stock Price Chart Interactive Chart >

Price chart for ALKS

ALKS Price/Volume Stats

Current price $22.85 52-week high $23.02
Prev. close $22.37 52-week low $11.98
Day low $22.30 Volume 1,335,426
Day high $23.02 Avg. volume 1,504,542
50-day MA $19.76 Dividend yield N/A
200-day MA $17.78 Market Cap 3.64B

Alkermes plc - Ordinary Shares (ALKS) Company Bio

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. The company was founded in 1987 and is based in Dublin, Ireland.

ALKS Latest News Stream

Event/Time News Detail
Loading, please wait...

ALKS Latest Social Stream

Loading social stream, please wait...

View Full ALKS Social Stream

Latest ALKS News From Around the Web

Below are the latest news stories about Alkermes plc that investors may wish to consider to help them evaluate ALKS as an investment opportunity.

Addiction Treatment Market Size, Top Key Players, Latest Trends, Regional Insights and Global Industry Dynamics By 2027 | Alkermes , Allergan, Cipla, GSK, Pfizer

When a person is addicted to a drug and if the person fails to control the urge, they are given addiction control treatment. This condition is concerned with illegal drugs, nicotine, painkillers, and alcohol. Usage of drugs regularly affects the

OpenPR | January 18, 2021

Novartis' (NVS) Ligelizumab Gets Breakthrough Therapy Status

Novartis (NVS) gets Breakthrough Therapy designation by the FDA for ligelizumab for the treatment of chronic spontaneous urticaria.

Yahoo | January 15, 2021

Marinus (MRNS) Gets Positive FDA Response for Ganaxolone Study

Marinus (MRNS) gets positive FDA response for phase III Marigold study on oral ganaxolone in children and young adults with CDKL5 deficiency disorder that appears sufficient to support the NDA filing.

Yahoo | January 14, 2021

NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine

Results from a National Institute on Drug Abuse (NIDA)-funded study evaluating the efficacy and safety of naltrexone for extended-release injectable suspension (XR-NTX) administered once every three weeks plus oral extended-release bupropion administered daily as a combination treatment for adults with moderate or severe methamphetamine use disorder (MUD) were published today by Dr. Madhukar H. Trivedi et al. in the New England Journal of Medicine (NEJM).1 This is the second published study evaluating this combination regimen for the treatment of MUD.2

Yahoo | January 14, 2021

The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) AbbVie Inc (NYSE: ABBV ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alkermes Plc (NASDAQ: ALKS ) AtriCure Inc. (NASDAQ: ATRC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) BIOLASE Inc (NASDAQ: BIOL ) (announced an agreement to expand laser adoption and hands-on training programs in targeted geographies) CareDx Inc (NASDAQ: CDNA ) Celsius Holdings, Inc. (NASDAQ: CELH ) DermTech Inc (NASDAQ: DMTK ) Dyne Therapeutics Inc (NASDAQ: DYN ) Edap Tms SA (NASDAQ: EDAP ) Evelo Biosciences Inc (NASDAQ: EVLO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Eyenovia Inc (NASDAQ: EYEN ) Genetron Holdings Ltd – ADR (NASDAQ...

Benzinga | January 13, 2021

Read More 'ALKS' Stories Here

ALKS Price Returns

1-mo 3.86%
3-mo 40.53%
6-mo 16.28%
1-year N/A
3-year -59.93%
5-year -32.18%
YTD 14.54%
2020 -2.21%
2019 -30.87%
2018 -46.08%
2017 -1.53%
2016 -29.98%

Continue Researching ALKS

Want to see what other sources are saying about Alkermes plc's financials and stock price? Try the links below:

Alkermes plc (ALKS) Stock Price | Nasdaq
Alkermes plc (ALKS) Stock Quote, History and News - Yahoo Finance
Alkermes plc (ALKS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8435 seconds.